- Home
- PIII vs SCYX Comparison
PIII vs SCYX Comparison
Compare PIII & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- SCYX
- Stock Information
- Founded
- PIII 2015
- SCYX 1999
- Country
- PIII United States
- SCYX United States
- Employees
- PIII N/A
- SCYX N/A
- Industry
- PIII Medical/Nursing Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- SCYX Health Care
- Exchange
- PIII Nasdaq
- SCYX Nasdaq
- Market Cap
- PIII 29.3M
- SCYX 32.3M
- IPO Year
- PIII N/A
- SCYX 2014
- Fundamental
- Price
- PIII $8.73
- SCYX $0.78
- Analyst Decision
- PIII Strong Buy
- SCYX
- Analyst Count
- PIII 3
- SCYX 0
- Target Price
- PIII $17.50
- SCYX N/A
- AVG Volume (30 Days)
- PIII 3.7K
- SCYX 697.5K
- Earning Date
- PIII 11-14-2025
- SCYX 11-13-2025
- Dividend Yield
- PIII N/A
- SCYX N/A
- EPS Growth
- PIII N/A
- SCYX N/A
- EPS
- PIII N/A
- SCYX N/A
- Revenue
- PIII $1,461,823,000.00
- SCYX $3,257,000.00
- Revenue This Year
- PIII N/A
- SCYX $20.23
- Revenue Next Year
- PIII $10.45
- SCYX $933.90
- P/E Ratio
- PIII N/A
- SCYX N/A
- Revenue Growth
- PIII 4.20
- SCYX N/A
- 52 Week Low
- PIII $5.80
- SCYX $0.66
- 52 Week High
- PIII $24.00
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- PIII 48.37
- SCYX 40.95
- Support Level
- PIII $8.60
- SCYX $0.76
- Resistance Level
- PIII $8.88
- SCYX $0.82
- Average True Range (ATR)
- PIII 0.31
- SCYX 0.06
- MACD
- PIII -0.06
- SCYX 0.00
- Stochastic Oscillator
- PIII 13.72
- SCYX 27.75
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.